Angiogenesis in rheumatoid arthritis

Frontiers in Bioscience

Volumn 10, Issue 2, 2005, Pages 1739-1753

  Szekanecz, Zoltán ^a   Gáspár, Levente ^a   Koch, Alisa Erika ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiogenesis; Angiogenic Mediators; Angiostatic Compounds; Endothelial Cells; Review; Rheumatoid Arthritis

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIC PROTEIN; ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; BETA1 INTEGRIN; BETA2 INTEGRIN; CELECOXIB; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHLOROQUINE; COLLAGEN TYPE 1; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GOLD SALT; HEPARIN; INDOMETACIN; LAMININ; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; ROFECOXIB; SALAZOSULFAPYRIDINE; SCLEROPROTEIN; TENASCIN; THALIDOMIDE; UNINDEXED DRUG;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CELL ACTIVITY; CLINICAL TRIAL; ENDOTHELIUM CELL; GENE CONTROL; GENE TARGETING; HUMAN; LEUKOCYTE; MOLECULAR DYNAMICS; NONHUMAN; PROGNOSIS; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALIA;

EID: 17244365963     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1657     Document Type: Article

References (160)

1. Z Szekanecz, G Szegedi, AE Koch. Angiogenesis in rheumatoid arthritis. J Investig Med 46:27-41 (1998)
2. AE Koch. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 41:951-962 (1998)
3. Z Szekanecz, AE Koch. Chemokines and angiogenesis. Curr Opin Rheumatol 13:202-208 (2001)
4. Z Szekanecz, AE Koch. Update on synovitis. Curr Rheumatol Rep 3:53-63 (2001)
5. W Auerbach, R Auerbach. Angiogenesis inhibition: a review. Pharmac Ther 63:265-311 (1994)
6. J Folkman, M Klagsbrun. Angiogenic factors. Science 235:442-447 (1987)
7. ED Harris Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 332:1277-1287 (1990)
8. Z Szekanecz, GK Haines, TR Lin, LA Harlow, S Goerdt, G Rayan, AE Koch. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 37:221-231 (1994)
9. AE Koch, JC Burrows, GK Haines, TM Carlos, J Harlan, SJ Leibovich. Immunolocalization of leukocyte and endothelial adhesion molecules in human rheumatoid and osteoarthritic synovial tissue. Lab Invest 64:313-320 (1991)
10. M Peichev, AJ Naiyer, D Pereira, Z Zhu, WJ Lane, M William, MC Oz, DJ Hicklin, L Witte, MA Moore, S Rafii. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952-958 (2000)
11. UM Gehling, S Ergun, U Schumacher, C Wagener, K Pantel, M Otte, G Schuch, P Schafhausen, T Mende, N Kilic, K Kluge, B Schafer, DK Hossfeld, W Fiedler. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106-3112 (2000)
12. SB Freedman, JM Isner. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 33:379-393 (2001)
13. AE Koch, W Turkiewicz, LA Harlow, RM Pope. Soluble E-selectin in arthritis. Clin Immunol Immunopathol 69:29-35 (1993)
14. H Sano, R Forough, JAM Maier, JP Case, A Jackson, K Engleka. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 110:1417-1426 (1990)
15. Z Qu, XN Huang, P Ahmadi, J Andresevic, SR Planck, CE Hart, JT Rosenbaum. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 73:339-346 (1995)
16. DH Goddard, SL Grossman, WV Williams, DB Weiner, JL Gross, K Eidsvoog. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 35:1296-1303 (1992)
17. AE Koch, LA Harlow, GK Haines, EP Amento, EN Unemori, WL Wong, RM Pope, N Ferrara. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149-4156 (1994)
18. RA Fava, NJ Olsen, G Spencer-Green, KT Yeo, TK Yeo, B Berse, RW Jackman, DR Senger, HF Dvorak, LF Brown. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341-346 (1994)
19. S Esser, K Wolburg, H Wolburg, G Breier, T Kurzchalia, W Risau. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947-959 (1998)
20. DS Grant, HK Kleinman, ID Goldberg, MM Bhargava, BJ Nickoloff, JL Kinsella, PJ Polverini, EM Rosen. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937-1941 (1993)
21. AE Koch, MM Halloran, S Hosaka, MR Shah, CJ Haskell, SK Baker, RJ Panos, GK Haines, GL Bennett, RM Pope, N Ferrara. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 39:1566-1575 (1996)
22. N Sato, JG Beitz, J Kato, M Yamamoto, JW Clark, P Calabresi, AR Frackelton Jr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 142:1119-1130 (1993)
23. EF Remmers, H Sano, RL Wilder. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Sem Arthritis Rheum 21:191-199 (1991)
24. M Takeuchi, T Otsuka, N Matsui, K Asai, T Hirano, A Moriyama. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 37:662-672 (1994)
25. J Kusada, T Otsuka, N Matsui, T Hirano, K Asai, T Kato. Immuno-reactive human epidermal growth factor (h-EGF) in rheumatoid synovial fluids. Nippon Seikeigeka Gakkai Zasshi 67:859-865 (1993.)
26. GM Keyszer, AH Heer, J Kriegsmann, T Geiler, C Keysser, RE Gay, S Gay. Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol 22:275-281 (1995)
27. DM Wiseman, PJ Polverini, DW Kamp, SJ Leibovich. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 157:793-800 (1988)
28. JA Hamilton, DS Piccoli, T Leizer, DM Butler, M Croatto, AK Royston. Transforming growth factor beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostaglandin E2 production, in human synovial fibroblasts. Proc Natl Acad Sci USA 88:7180-7184 (1991)
29. ME Brandes, JB Allen, Y Ogawa, SM Wahl. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 87:1108-1113 (1991)
30. Z Szekanecz, GK Haines, LA Harlow, MR Shah, TW Fong, R Fu, SJ-W Lin, G Rayan, AE Koch. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76:187-194 (1995)
31. A Giatromanolaki, E Sivridis, E Maltezos, N Athanassou, D Papazoglou, KC Gatter, AL Harris, MI Koukourakis. Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 5: R193-R198 (2003)
32. PJ Etherington, P Winlove, P Taylor, E Paleolog, JM Miotla. VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Clin Exp Rheumatol 20:199-805 (2002)
33. CC Park, JC Morel, MA Amin, MA Connors, LA Harlow, AE Koch. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167:1644-1653 (2001)
34. E Voronov, DS Shouval, Y Krelin, E Cagnano, D Benharroch, Y Iwakuchi, CA Dinarello, RN Apte. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645-2650 (2003)
35. AL Angiolillo, H Kanegane, C Sgadari, GH Reaman, G Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 233:231-237 (1997)
36. MM Halloran, CJ Haskell, JM Woods, S Hosaka, AE Koch. Interleukin-13 is an endothelial chemotaxin. Pathobiology 65:287-292 (1997)
37. ES Wijelath, B Carlsen, T Cole, J Chen, S Kothari, WP Hammond. Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology. J Cell Sci 110:871-879 (1997)
38. SJ Leibovich, PJ Polverini, HM Shepard, DM Wiseman DM, V Shively, N Nuseir. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329:630-632 (1987)
39. AE Koch, PJ Polverini, SL Kunkel, LA Harlow, LA DiPietro, VM Elner, SG Elner, RM Strieter. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801 (1992)
40. AE Koch, PJ Polverini, SJ Leibovich. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum 29:471-479 (1986)
41. E Lupia, G Montrucchio, E Battaglia, V Modena, G Camussi. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 26:1690-1694 (1996)
42. A Coxon, B Bolon, J Estrada, S Kaufman, S Scully, A Rattan, D Duryen, YL Hu, K Rex, E Pacheco, G Van, D Zack, U Feige U. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 46:2604-2612 (2002)
43. FM Brennan, M Field, CQ Chu, M Feldmann, RN Maini. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 30:76-80 (1991)
44. A Shore, S Jaglal, EC Keystone. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 65:293-302 (1986)
45. EM Rosen, D Liu, E Setter, M Bhargava, ID Goldberg. Interleukin-6 stimulates motility of vascular endothelium. EXS 59:194-205 (1991)
46. L Sachs. Angiogenesis - cytokines as part of a network. EXS 59:20-22 (1991)
47. FA Houssiau, J-P Devogelaer, J Van Damme, CN De Deuxchaisnes, J Van Snick. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784-788 (1988)
48. M Field, C Chu, M Feldmann, RN Maini. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 11:45-50 (1991)
49. P Isomaki, R Luukkainen, P Toivanen, J Punnonen. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 39:1693-1702 (1996)
50. JM Woods, GK Haines, MR Shah, AE Koch. Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis. Arthritis Rheum 39:S129 (1996)
51. JM Woods, MA Amin, KJ Katschke jr, MV Volin, JH Ruth, MA Connors, DC Woodruff, H Kurata, K Arai, GK Haines, P Kumar, AE Koch. Interleukin-13 gene therapy reduces inflammation, vascularization and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 13:381-393 (2002)
52. IB McInnes, J Al-Mughales, M Field, BP Leung, F Huang, R Dixon, RD Sturrock, PC Wilkinson, FY Liew. The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med 2:175-182 (1996)
53. JA Gracie, RJ Forsey, WL Chan, A Gilmour, BP Leung, MR Greer, K Kennedy, R Carter, XQ Wei, D Xu, M Field, A Foulis, FY Liew, IB McInnes. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393-1401 (1999)
54. JM Alvaro-Garcia, NJ Zvaifler, GS Firestein. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 170:865-875 (1989)
55. H Okamoto, M Yamamura, Y Morita, S Harada, H Makino, Z Ota. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 40:1096-1105 (1997)
56. RM Strieter, SL Kunkel, AB Shanafelt, DA Arenberg, AE Koch & PJ Polverini. The role of C-X-C chemokines in regulation of angiogenesis. In: Chemokines in disease. Eds: AE Koch, RM Strieter. RG Landes Company, Austin, 195-209 (1996)
57. RM Strieter, PJ Polverini, SL Kunkel, DA Arenberg, MD Burdick, J Kasper, J Dzuiba, J Van Damme, A Walz, D Marriott, S-Y Chan, S Roczniak, AB Shanafelt. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348-27357 (1995)
58. A Walz, SL Kunkel, RM Strieter. C-X-C chemokines - an overview. In: Chemokines in disease. Eds: AE Koch, RM Strieter, RG Landes Company, Austin, 1-25 (1996)
59. AE Koch, SL Kunkel, RM Strieter. Chemokines in arthritis. In: Chemokines in disease. Eds: AE Koch, RM Strieter. RG Landes Company, Austin, 103-116 (1996)
60. MV Volin, JM Woods, MA Amin, MA Connors, LA Harlow, AE Koch. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 159:1521-1526 (2001)
61. S Hosaka, T Akahoshi, C Wada, H Kondo. Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 97:451-457 (1994)
62. AE Koch, MV Volin, JM Woods, SL Kunkel, MA Connors, LA Harlow, DC Woodruff, MD Burdick, RM Strieter. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide-78 in the rheumatoid joint. Arthritis Rheum 44:31-40 (2001)
63. AE Koch, SL Kunkel, LA Harlow, DD Mazarakis, GK Haines, MD Burdick, RM Pope, A Walz, RM Strieter RM. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 94:1012-1018 (1994)
64. AE Koch, SL Kunkel, MR Shah, S Hosaka, MM Halloran, GK Haines, MD Burdick, RM Pope, RM Strieter. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 155:3660-3666 (1995)
65. CW Castor, EM Smith, PA Hossler, MC Bignall, BP Aaron. Detection of connective tissue activating peptide-III isoforms in synovium from osteoarthritis and rheumatoid arthritis patients: patterns of interaction with other synovial cytokines in cell culture. Arthritis Rheum 35:783-793 (1992)
66. R Salcedo, K Wasserman, HA Young, MC Grimm, OM Howard, MR Anver, HK Kleinman, WJ Murphy, JJ Oppenheim. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125-1135 (1999)
67. CD Buckley, N Amft, PF Bradfield, D Pilling, E Ross, F Arenzana-Seisdedos, A Amara, SJ Curnow, JM Lord, D Scheel-Toellner, M Salmon. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165:3423-3429 (2000)
68. T Nanki, K Hayashida, HS El-Gabalawy, S Suson, K Shi, HJ Girschick, S Yavuz, PE Lipsky. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165:6590-6598 (2000)
69. R Salcedo, ML Ponce, HA Young, K Wasserman, JM Ward, HK Kleinman, JJ Oppenheim, WJ Murphy. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40 (2000)
70. AE Koch, SL Kunkel, LA Harlow, B Johnson, HL Evanoff, GK Haines, MD Burdick, RM Pope, RM Strieter. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772-779 (1992)
71. . U Schonbeck, E Brandt, F Petersen, HD Flad, H Loppnow. IL-8 specifically binds to endothelial but not to smooth muscle cells. J Immunol 154, 2375-2383 (1995.)
72. N Rinaldi, M Schwarz-Eywill, D Weis, P Leppelmann-Jansen, M Lukoschek, U Keilholz, TF Barth TF. Increased expression of integrals on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 56:45-51 (1991.)
73. CL Addison, TO Daniel, MD Burdick, H Liu, JE Ehlert, YY Xue, L Buechi, A Walz, A Richmond, RM Strieter. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165:5269-5277 (2000)
74. JH Ruth, JB Rottman, KJ Katschke jr, S Qin, L Wu, G LaRosa, P Ponath, RM Pope, AE Koch. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 44:2750-2760 (2001)
75. H Bruhl, J Cihak, MA Schneider, J Plachy, T Rupp, I Wenzel, M Shakarami, S Milz, JW Ellwart, M Stangassinger. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ cells. J Immunol 172:890-898 (2004)
76. JA Madri, KS Williams. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97:153-165 (1983)
77. RF Nicosia, E Bonanno, M Smith. Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 154:654-661 (1993)
78. AE Canfield, AM Schor. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 108:797-809 (1995)
79. N Rinaldi, M Schwarz-Eywill, D Weis, P Leppelmann-Jansen, M Lukoschek, U Keilholz, TF Barth. Increased expression of integrins on fibrob last-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 56:45-51 (1991)
80. S Maeda, T Sawai, M Uzuki, Y Takahashi, H Omoto, M Seki, M Sakurai. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 54:970-975 (1995)
81. RM Hembry, MR Bagga, JJ Reynolds, DL Hamblen. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54:25-32 (1995)
82. Z Szekanecz, GK Haines, AE Koch. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol 50:314-319 (1997)
83. C Belcher, F Fawthrop, R Bunning, M Doherty. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 55:230-236 (1996)
84. MN Vankemmelbeke, I Holen, AG Wilson, MZ Ilic, CJ Handley, GS Kelner, M Clark, C Liu, RA Maki, D Burnett, DJ Buttle. Expression and activity of ADAMTS-5 in synovium. Eur J Biochem 268:1259-1268 (2001)
85. Z Szekanecz, G Szegedi, AE Koch. Cellular adhesion molecules in rheumatoid arthritis. Regulation by cytokines and possible clinical importance. J Investig Med 44:124-135 (1996)
86. DO Haskard. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 7:229-234 (1995)
87. AE Koch, MM Halloran, CJ Haskell, MR Shah, PJ Polverini. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519 (1995)
88. PC Brooks, RA Clark, DA Cheresh. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571 (1994.)
89. ER Horak, R Leek, N Klenk, S LeJeune, K Smith, N Stuart, M Greenall, K Stepniewska, AL Harris. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124 (1992)
90. JA Maier, D Delia, PE Thorpe, G Gasparini. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antiody TEC-11. Anticancer Drugs 8:238-244 (1997)
91. P Kumar, JM Wang, C Bernabeu. CD 105 and angiogenesis [editorial]. J Pathol 178:363-366 (1999)
92. H El Gabalawy, J Wilkins. Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: an immunohistologic study of distribution patterns. J Rheumatol 20:231-237 (1993)
93. DR Senger, KP Claffey, JE Benes, CA Perruzzi, AP Sergiou, M Detmar. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc Natl Acad Sci USA 94:13612-13617 (1997)
94. SM Wellicome, P Kapahi, JC Mason, Y Lebranchu, H Yarwood, DO Haskard. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 92:412-418 (1993)
95. LS Wilkinson, JCW Edwards, RN Poston, DO Haskard. Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest 68:82-88 (1993)
96. L Morbidelli, L Brogelli, HJ Granger, M Ziche. Endothelial cell migration is induced by soluble P-selectin. Life Sci 62:7-11 (1998)
97. S Hosaka, MR Shah, RM Pope, AE Koch. Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Clin Immunol Immunopathol 78:276-282 (1996)
98. Z Szekanecz, GK Haines, LA Harlow, MR Shah, TW Fong, R Fu, SJ-W Lin, AE Koch. Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin Immunol Immunopathol 76:180-186 (1995)
99. MM Halloran, WW Carley, PJ Polverini, CJ Haskell, S Phan, BJ Anderson, JM Woods, PL Campbell, MV Volin, AE Backer, AE Koch. Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol 164, 4868-4877 (2000)
100. M Neidhart, R Wehrli, P Bruhlmann, BA Michel, RE Gay, S Gay. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis Rheum 42, 622-630 (1999)
101. KM Leahy, AT Koki, JL Masferrer. Role of cyclooxygenases in angiogenesis. Curr Med Chem 7:1163-1170 (2000)
102. HS Cha, KS Ahn, CH Jeon, J Kim, EM Koh. Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 24, 207-211 (2004)
103. JM Woods, A Mogollon, MA Amin, RJ Martinez, AE Koch. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74:282-290 (2003)
104. T Pufe, M Bartscher, W Petersen, B Tillmann, R Mentlein. Expression of pleiotrophin an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 48:660-667 (2003)
105. F Liote, R Champy, M Moenner, B Boval-Boizard, J Badet. Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol 132:163-168 (2003)
106. S Davis, TH Aldrich, PF Jones, A Acheson, DL Compton, V Jain, TE Ryan, J Bruno, C Radziejewski, PC Maisonpierre, GD Yancopoulos. isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169 (1996)
107. S Shahrara, MV Volin, MA Connors, GK Haines, AE Koch. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 4:201-208 (2002)
108. G Camussi, G Montrucchio, E Lupia, A De Martino, L Perona, M Arese, A Vercellone, A Toniolo, F Bussolino. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 154:6492-6501 (1995)
109. P Hilliquin, P Guinot, V Chermat-Izard, X Puechal, CJ Menkes. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 22:1651-1654 (1995)
110. CJ Menkes, M Renoux, S Laoussadi, A Mauborgne, J Bruxelle, F Cesselin. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 20:714-717 (1993)
111. E Sugiyama, A Kuroda, H Taki, M Ikemoto, T Hori, N Yamashita, M Maruyama, M Kobayashi. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 22:2020-2026 (1995)
112. AE Koch, TW Fong, OV Volpert, MM Halloran, NP Bouck. Interleukin-4 is an inhibitor of angiogenesis. Arthritis Rheum 39:S304 (1996)
113. EE Voest, BM Kenyon, MS O'Reilly, G Truitt, RJ D'Amato, J Folkman. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586 (1995)
114. A Angiolillo, C Sgadari, G Tosato. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 795:158-167 (1996)
115. JF Schlaak, I Pfers, KH Meyer Zum Buschenfelde, E Marker Hermann. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 14:155-162 (1996)
116. PM Waring, GJ Carroll, DA Kandiah, G Buirski, D Metcalf. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 36:911-915 (1993)
117. RM Strieter, SL Kunkel, DA Arenberg, MD Burdick, PJ Polverini. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 210:51-57 (1995)
118. DD Patel, JP Zachariah, LP Whichard. CXCR3 and CCR5 ligands in the rheumatoid arthritis synovium. Clin Immunol 98:39-45 (2001)
119. PH Wooley, C Schaefer, JD Whalen, JA Dutcher, DF Counts. A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol 24:890-898 (1997)
120. AP Vicari, S Ait-Yahia, K Chemin, A Mueller, A Zlotnik, C Caux. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165:1992-2000 (2000)
121. S Qin, JB Rottman, P Myers, N Kassam, M Weinblatt, M Loetscher, AE Koch, B Moser, CR Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells with homing predilection for certain inflammatory sites. J Clin Invest 101:746-750 (1998)
122. JS Skotnicki, A Zask, FC Nelson, JD Albright, JI Levin. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann NY Acad Sci 878:61-72 (1999)
123. F Apparailly, C Bouquert, V Millet, D Noel, C Jacquet, P Opolon, M Perricaudet, J Sany, P Yeh, C Jorgensen. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. Gene Ther 9:192-200 (2002)
124. AE Koch, J Friedman, JC Burrows, GK Haines, NP Bouck. Immunolocalization of the angiogenesis inhibitor thrombospondin in human arthritic synovial tissues. Pathobiology 161:1-6 (1993)
125. AE Koch, Z Szekanecz, J Friedman, GK Haines, CB Langman, NP Bouck. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol, 86:199-208 (1998)
126. JW Mall, JA Myers, X Xu, TJ Saclarides, AW Philipp, C Pollmann. Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in a mouse model. Chirurg 73:716-720 (2002.)
127. GS Firestein, MM Paine, DL Boyle. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum 37:193-200 (1994)
128. AE Koch, M Cho, J Burrows, SJ Leibovich, PJ Polverini. Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun 154:205-212 (1988)
129. SJ Oliver, TP Cheng, ML Banquerigo, E Brahn. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 166:196-206 (1995)
130. YS Lin, C Nguyen, JL Mendoza, E Escandon, D Fei, YG Meng, NB Modi. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378 (1999)
131. EJ Kucharz, J Gozdzik, M Kopec, A Kotulska, M Lewicki, R Pieczyrak, M Widuchowska, H Zakliczynska, M Szarczynska-Ruda, I Zycinska, E Debska. A single infusion of infliximab increases the serum endostatin leveli n patients with rheumatoid arthritis. Clin Exp Rheumatol 21:273-274 (2003)
132. E Josefsson, A Tarkowski. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 40:154-163 (1997)
133. PR Colville-Nash, M El-Ghazaly, DA Willoughby. The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation. Agents Actions 38:126-134 (1993)
134. SJ Oliver, ML Banquerigo, E Brahn. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 157:291-299 (1994)
135. KL Sewell, F Breedveld, E Furrie, J O'Brien, C Brinckerhoff, R Dynesius-Trentham, Y Nosaka, DE Trentham. The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol 167:195-204 (1996)
136. DE Trentham, RA Dynesius-Trentham. Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Rheum Dis Clin North Am 27:817-834 (1995)
137. M Kloppenburg, FC Breedveld, JP Terwiel, C Mallee, BA Dijkmans. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 57:629-636 (1994)
138. K Nemoto, T Mae, F Abe, T Takeuchi. Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice. Ann N Y Acad Sci 685P:148-154 (1993)
139. J Yatsunami, N Turuta, K Wakamatsu, N Hara, S Hayashi. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. Res Exp Med Berl 197:189-197 (1997)
140. N Matsuoka, K Eguchi, A Kawakami, M Tsuboi, Y Kawabe, T Aoyagi, S Nagataki. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 104:501-508 (1996)
141. K Setoguchi, Y Misaki, K Kawahata, K Shimada, T Juji, S Tanaka, H Go, C Shukunami, Y Nishizaki, Y Hiraki, K Yamamoto. Suppression of T cell responses by chondromodulin 1, a cartilage-derived angiogenesis inhibitory factor: therapeutic potential in rheumatoid arthritis. Arthritis Rheum 50:828-839 (2004)
142. S Nakamura, K Kamihagi, H Satakeda, M Katayama. Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage: increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum 39:539 (1996)
143. JL Wilson, V Nayanar, JS Walker. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration. Br J Pharmacol 118:1754-1760 (1996)
144. JS Walker, AK Chandler, JL Wilson, W Binder, RO Day. Effect of mu-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats. Inflamm Res 45:557-563 (1996)
145. PC Maisonpierre, C Suri, PF Jones, S Bartunkova, SJ Wiegand, C Radziejewski, D Compton, J McClain, TH Aldrich. N Papadopoulos, TJ Daly, S Davis, TN Sato, GD Yancopoulos. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60 (1997)
146. MS O'Reilly, L Holmgren, Y Shing, C Chen, RA Rosenthal, M Moses, WS Lane, Y Cao, EH Sage, J Folkman. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328 (1994)
147. D Kurosaka, K Yoshida, J Yasuda, T Yokoyama, I Kingetsu, N Yamaguchi, K Joh, M Matsushima, S Saito, A Yamada. Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis 62:677-679 (2003)
148. H Matsuno, K Yudoh, M Uzuki, F Nakazawa, T Sawai, N Yamaguchi, BR Olsen, T Kimura. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol 29:890-895 (2002)
149. G Yin, W Liu, P An, P Li, I Ding, V Planelles, EM Schwarz, W Min. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 5:547-554, 2002.
150. JM Kim, SH Ho, EJ Park, W Hahn, H Cho, JG Jeong, YW Lee, J Kim. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 46:793-801 (2002.)
151. PF Sumariwalla, Y Cao, HL Wu, M Feldmann, EM Paleolog. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5:R32-R39 (2003.)
152. ACHM van Dinther-Janssen, E Horst, G Koopman, W Newmann, RJ Scheper, CJ Meijer, ST Pals. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 147:4207-4210 (1991)
153. J Martel-Pelletier, R McCollum, N Fujimoto, K Obata, JM Cloutier, JP Pelletier. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 70:807-815 (1994)
154. G Taraboletti, D Belotti, R Giavazzi. Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. EXS 59:210-213 (1991)
155. G Kingsley, G Panayi, J Lanchbury. Immunotherapy of rheumatic diseases - practice and prospects. Immunol Today 12:177-179 (1991)
156. I Saiki, J Murata, T Makabe, N Nishi, S Tokura, I Azuma. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD R). Jpn J Cancer Res 81:668-675 (1990)
157. PW Manley, G Martiny-Baron, JM Schlaeppi, JM Wood. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 77:1715-1736 (2002)
158. M Shibuya. VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi 122:498.503 (2003)
159. MM Corkill, BW Kirkham, DO Haskard, C Barbatis, T Gibson, GS Panayi. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 18:1453-1460 (1991)
160. RL Wilder. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61 Suppl 2:ii96-ii99 (2002)